Research and Markets (http://www.researchandmarkets.com/research/8vbwjl/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Psychosis Overview
- Therapeutics Development
- Pipeline Products for Psychosis - Overview
- Pipeline Products for Psychosis - Comparative Analysis
- Psychosis - Therapeutics under Development by Companies
- Psychosis - Therapeutics under Investigation by Universities/Institutes
- Psychosis - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Psychosis - Products under Development by Companies
- Psychosis - Products under Investigation by Universities/Institutes
- Psychosis - Companies Involved in Therapeutics Development
- Acadia Pharmaceuticals Inc.
- Addex Therapeutics Ltd
- Eli Lilly and Company
- Evotec AG
- Gabather AB
- Glenmark Pharmaceuticals Ltd.
- Heptares Therapeutics Limited
- Integrative Research Laboratories Sweden AB
- Newron Pharmaceuticals S.p.A.
- Reviva Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Sunovion Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/8vbwjl/psychosis
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006098/en/
